Team
We are a diverse group – molecular biologists, MDs, PharmDs, tumor immunologists, stem cell biologists and computational scientists – at all career stages. We architect strategies to dissect and manipulate immune cell identity.
Members
Alumni
Cristiana Pires
Former Postdoctoral Fellow
Currently CEO at Asgard Therapeutics AB, Sweden
Rita Silvério-Alves
Former PhD Student - FCT Fellow
Currently Postdoc Fellow at Novo Nordisk Foundation Center for Stem Cell Medicine, Denmark
Fábio Rosa
Former PhD Student - FCT Fellow
Currently Head of Research at Asgard Therapeutics AB, Sweden
Alexandra Gabriela Ferreira
Former PhD Student - FCT Fellow
Currently Research Scientist at BioInvent International AB, Sweden
Andreia Gomes
Former PhD Student
Currently Global Product Manager at Miltenyi Biotec, Germany
Frederick Korbel
Former BSc Student
Currently PhD Student at Max-Delbrück-Center for Molecular Medicine, Berlin, Germany
Nina Lipjankić
Former MSc Student
Currently Research Associate at Acrivon AB, Sweden
Luis Galán Palma
Former Erasmus Student
Currently Postdoctoral Fellow at Anna Bigas lab, Hospital del Mar Research Institutes, Barcelona, Spain
Tasnim Zahan
Former MSc Student
Currently Process Development Technician at Immunicum AB, Sweden
Collaborators
Inge Marie Svane
Copenhagen University Hospital
Clinical. Melanoma. Copenhagen, Denmark
Katharina Lahl
Lund University
Dendritic Cells. Lund, Sweden
Javier Martin Gonzalez
University of Copenhagen
Transgenic Mouse Model Generation. Copenhagen, Denmark
Andreas Bender
University of Cambridge
Molecular Informatics. Cambridge, U.K.
Malin Lindstedt & Lennart Greiff
Lund University
Clinical. Head and Neck. Lund, Sweden
Anna-Lena Gustavsson
Scilifelab
Small Molecule Screening. Stockholm, Sweden
Raquel Almeida
I3S - University of Porto
Cancer Stem Cells. Porto, Portugal
Irina Agarkova
Insphero AG
Spheroids. Schlieren, Switzerland
Valentina Cauda
Polytechnic University of Turin
Nanoparticles. Turin, Italy
Spin-Offs
Asgard Therapeutics
An important hallmark of cancer is the ability to evade the immune system. Asgard Therapeutics has the goal to establish dendritic cell reprogramming as an entirely new approach to unleash the immune system against cancer.
Blood Reprogramming Technologies
Blood Reprogramming Technologies is a biotechnology start-up focused on the use of direct cell reprogramming to generate innovative solutions for hematopoietic stem cell transplantation and blood regeneration.
